tzield
Generic: teplizumab-mzwv
tzield: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
tzield evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
Source-backed records connect tzield to PRVB; that link alone does not prove the drug works.
What to watch
Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected
Prepared research question
How could tzield → PRVB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged eight years and older with Stage 2 T1D
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PROVENTION BIO, INC. (PRVB) Delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult an… | Approved |
Clinical Trials (1)
An Observational, Long-term Safety Study of TZIELD® (Teplizumab-mzwv) in Patients With Stage 2 Type 1 Diabetes
Primary endpoint: Number of adverse events of special interests (AESI)
Observational200 targetStarted 2024-09Completion 2037-0137 sites · United StatesSanofi
FDA Decisions1 records
Frequently asked questions
Who is developing tzield?
tzield is being developed by PROVENTION BIO, INC..
How many clinical trials involve tzield?
BioSniper tracks 1 clinical trial involving tzield.
What is tzield's latest FDA decision?
The most recent tracked FDA decision for tzield is Approval, dated November 17, 2022.